- Home
- IPSC vs ESLA Comparison
IPSC vs ESLA Comparison
Compare IPSC & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- ESLA
- Stock Information
- Founded
- IPSC 2019
- ESLA 2021
- Country
- IPSC United States
- ESLA United States
- Employees
- IPSC N/A
- ESLA N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IPSC Health Care
- ESLA Health Care
- Exchange
- IPSC Nasdaq
- ESLA Nasdaq
- Market Cap
- IPSC 49.1M
- ESLA 48.9M
- IPO Year
- IPSC 2021
- ESLA N/A
- Fundamental
- Price
- IPSC $0.57
- ESLA $1.69
- Analyst Decision
- IPSC Strong Buy
- ESLA Strong Buy
- Analyst Count
- IPSC 5
- ESLA 1
- Target Price
- IPSC $3.33
- ESLA $16.00
- AVG Volume (30 Days)
- IPSC 730.7K
- ESLA 191.8K
- Earning Date
- IPSC 11-04-2025
- ESLA 11-20-2025
- Dividend Yield
- IPSC N/A
- ESLA N/A
- EPS Growth
- IPSC N/A
- ESLA N/A
- EPS
- IPSC N/A
- ESLA N/A
- Revenue
- IPSC $114,128,000.00
- ESLA N/A
- Revenue This Year
- IPSC $1,589.94
- ESLA N/A
- Revenue Next Year
- IPSC N/A
- ESLA N/A
- P/E Ratio
- IPSC N/A
- ESLA N/A
- Revenue Growth
- IPSC 5491.77
- ESLA N/A
- 52 Week Low
- IPSC $0.34
- ESLA $0.63
- 52 Week High
- IPSC $1.83
- ESLA $1.80
- Technical
- Relative Strength Index (RSI)
- IPSC 60.85
- ESLA 73.27
- Support Level
- IPSC $0.52
- ESLA $1.20
- Resistance Level
- IPSC $0.62
- ESLA $1.80
- Average True Range (ATR)
- IPSC 0.03
- ESLA 0.18
- MACD
- IPSC 0.01
- ESLA 0.04
- Stochastic Oscillator
- IPSC 64.94
- ESLA 82.32
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.